Coronary Drug Eluting Stent Market Overview
The coronary drug eluting stent market, valued at USD 4.04 billion in 2025, is projected to reach USD 4.50 billion in 2026 and USD 9.38 billion by 2035, with a 8.51% CAGR during the forecast period 2026 to 2035.
To learn more about this report, request a free sample copy
Cardiovascular diseases (CVD) are reported to be one of the leading causes of deaths across the globe, surpassing conditions, such as cancer and respiratory disorders. According to the WHO, around one third of the annual global deaths (an estimated 18 million) can be attributed to cardiac disorders. Specifically, coronary artery disease (CAD) is the most common form of cardiovascular disorder; around 11 million deaths were linked to this indication in 2020. It is worth mentioning that, in 2020 (post the onset of the pandemic), a more than 3% increase in the deaths related to heart diseases was reported.
Further, according to the Centers for Disease Control and Prevention, the financial burden (in terms of annual medical costs and loss of productivity) associated with cardio vascular diseases is expected to be surpass USD 1,000 billion, in 2030. In order to prevent the critical effects of vessel narrowing and plaque buildup in arteries, various coronary interventional devices are being used; coronary drug eluting stent (DES) / cardiac stent have emerged as one of the most preferred solutions to mitigate the aforementioned concerns. Traditionally, bare-metal stent (BMS) was used extensively to open the blocked passages and restore adequate blood flow to the heart.
In recent years, a shift in preference has been observed towards the use of drug-eluting stent (DES), which are coated with a polymer carrying an antiproliferative drug. Such cardiac stents have been demonstrated to reduce / prevent in-stent restenosis (re-narrowing of the arteries previously opened using angioplasty), which was a major complication associated with the use of bare-metal stents. Cardiac stents are considered to be revolutionary in the interventional cardiology domain, as they enable improved revascularization rates and reduced risk of thrombosis.
Presently, over 90 cardiovascular drug eluting stents are being offered by around 40 players located across the globe. Majority of such devices employ the use of metals, such as platinum chromium and stainless steel. Further, the patents focused on cardiovascular drug eluting stents and associated technologies have been filed / granted at a CAGR of 13%, in the past two decades. In this context, it is important to note that, over the past few years, there have been significant innovations in cardiovascular therapeutics domain, in terms of development of advanced bioresorbable stents, drug combinations, medical polymers and nanomaterial coatings, to further increase the safety and efficacy of these treatment options. For instance, recently, an implantable biocompatible stent containing miniaturized ultrasonic transducers have been proposed by a group of researchers, which can be used for real-time monitoring of restenosis in the patients. Moreover, recent advancements related to the use of augmented reality and deep learning can enable the development of patient-specific stents, paving the way for personalized-treatment for patients suffering from cardiovascular disorders. Given the ongoing pace of innovation in coronary drug eluting stent market, adoption of cutting-edge technologies by device developers, the ever-increasing incidence of heart diseases and the rise in demand for associated treatments, we believe that the cardiovascular drug eluting stent market is likely to witness a significant market growth during the forecast period.
Key Companies in Coronary Drug Eluting Stent Market
Examples of key companies engaged in coronary drug eluting stent market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Alvimedica, B. Braun, Boston Scientific, Cook Medical, Eurocor Scientific, Lepu Medical, Medtronic, Meril, Relisys and Sahajanand Medical Technologies. This coronary drug eluting stent market report includes an easily searchable excel database of all the companies providing drug eluting stent for cardiovascular disorders, worldwide.
Recent Developments in Coronary Drug Eluting Stent Market
Several recent developments have taken place in the field of coronary drug eluting stent. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
- In April 2026, FDA granted premarket approval supplement for Medtronic's Onyx Frontier Zotarolimus Eluting Coronary Stent System, a coronary drug-eluting stent, enhancing treatment options for coronary artery disease patients in the US market.
- In April 2026, FDA issued premarket approval supplement for Medinol's EluNIR Ridaforolimus Eluting Coronary Stent System, classified as a coronary drug-eluting stent, supporting advanced percutaneous coronary interventions.
- In March 2026, FDA approved premarket approval supplement for Abbott's XIENCE family stents, including XIENCE Alpine, Sierra, and Skypoint Everolimus Eluting Coronary Stent Systems, advancing drug-eluting stent technology for coronary applications.
- In March 2026, Terumo Corporation received FDA clearance detailed in K252295 for a balloon-expandable coronary drug-eluting stent system, focusing on post-deployment expansion capabilities for improved vessel patency in cardiac procedures.
- In December 2025, Medtronic entered into a collaboration with a medical device innovator to co-develop next-generation drug-eluting stents featuring improved biocompatibility, aiming to enhance patient outcomes in cardiovascular care globally.
Scope of the Coronary Drug Eluting Stent Market Report
The “Coronary Drug Eluting Stent Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the companies involved in cardiovascular drug eluting stent market. The market research report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market space.
Amongst other elements, the market report includes:
- A detailed overview of the current market landscape of the players engaged in developing / manufacturing cardiovascular drug eluting stents, including information on their respective year of establishment, company size (in terms of number of employees), number of products offered and location of headquarters. Further, it provides a detailed assessment of the overall landscape of over 90 cardiovascular drug eluting stents, based on several relevant parameters, such as type of eluted drug, type of cardiac stent material, post dilatation limit, stent length, stent diameter, nominal pressure, rated burst pressure and administered drug concentration.
- An in-depth analysis, highlighting the contemporary market trends, using five schematic representations, including a heat map representation (based on type of drug eluted and administered drug concentration), a stacked bar chart representation (by the type of drug eluted and stent material), a tree map representation (based on maximum stent length and maximum stent diameter), a 4D bubble chart representation comparing the players engaged in cardiovascular drug eluting stents domain (based on several relevant parameters (such as year of establishment, company size, number of products offered and location of headquarters)) and a grid representation (based on company size, number of products offered, maximum stent length, maximum stent diameter and location of headquarters).
- An insightful company competitiveness analysis of cardiovascular drug eluting stent developers, taking into consideration various relevant parameters, such as year of experience and portfolio strength (in terms of number of products offered, stent material, maximum stent length, maximum stent diameter, maximum nominal pressure, maximum rated burst pressure, and lowest strut thickness).
- Elaborate profiles of various prominent players that are currently engaged in developing / manufacturing drug eluting stents employed for the treatment of cardiovascular disorders, featuring a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters, key members of the executive team and cardiovascular drug delivery device portfolio), recent developments and an informed future outlook.
- An in-depth analysis of the various patents that have been filed / granted related to cardiovascular drug eluting stents, based on various parameters, such as patent type, publication year, geographical location, CPC symbol, emerging focus areas, type of applicant and leading industry / non-industry players (in terms of the size of intellectual property portfolio). Further, it features a three-dimensional bubble analysis (based on patent citation count, publication year, extended geographical reach), patent benchmarking analysis and a detailed patent valuation analysis.
- An insightful case study focused on novel cardiovascular therapeutics (such as gene therapy, next generation complements, oral proteins and peptides, regulatory t-cell (tregs) therapies and subcutaneous biologics) and novel cardiovascular-based services / solutions (such as biopharmaceutical contract research offerings, digital therapeutics and precision medicine software). It also features a list of developers, along with details on their year of establishment, company size and location of headquarters.
- An elaborate analysis in order to estimate the current and future demand for cardiovascular drug eluting stents, based on several relevant parameters, such as type of drug eluted (sirolimus, paclitaxel, everolimus, zotarolimus and others), type of cardiac stent material (platinum chromium, cobalt chromium, stainless steel and others) and key geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World) for the forecast period till 2035. Kindly note that input parameters considered for this analysis include number of patients suffering from cardiovascular disorders that can be treated using cardiovascular drug eluting stents and average price of such stents across various geographies.
One of the key objectives of this market report is to provide a detailed market forecast analysis in order to estimate the existing market size and future opportunity for coronary drug eluting stent market during forecast period. Based on several parameters, such as annual cases reported for cardiovascular disorders, percutaneous coronary interventions performed (in terms of number of patients) to treat such disorders, and average price for associated cardiac stent across various geographical regions, we have provided an informed estimate on the evolution of the market for the forecast period till 2035. The report also features the likely distribution of the current and forecasted opportunity related to coronary drug eluting stent market across type of drug eluted (sirolimus, paclitaxel, everolimus, zotarolimus and others), type of cardiac stent material (platinum chromium, cobalt chromium, stainless steel and others) and key geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World). In order to account for future uncertainties and add robustness to our forecast model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
 |
 |
|
The opinions and insights presented in the market report were influenced by discussions held with multiple stakeholders in coronary drug eluting stent market. The market research report features detailed transcripts of interviews held with several industry stakeholders.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.
Frequently Asked Questions
Question 1: What are drug eluting stents?
Answer: Drug eluting stents are drug coated stents used in interventional cardiology industry. They are coated with a polymer carrying an antiproliferative drug and have demonstrated reduction / prevention of in-stent restenosis.
Question 2: What is the market size for coronary drug eluting stents?
Answer: The coronary drug eluting stent market size is estimated to be worth $4.50 billion in 2026.
Question 3: What is the projected market growth of the coronary drug eluting stent market?
Answer: The coronary drug eluting stent market is expected to grow at compounded annual growth rate (CAGR) of 8.51% during the forecast period.
Question 4: Who is the leading manufacturer of coronary drug eluting stent?
Answer: Examples of key companies engaged in coronary drug eluting stent market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Alvimedica, B. Braun, Boston Scientific, Cook Medical, Eurocor Scientific, Lepu Medical, Medtronic, Meril, Relisys and Sahajanand Medical Technologies.
Question 5: How many patents related to the coronary drug eluting stent and associated technologies have been filed / granted till date?
Answer: Till date, over 900 patents related to the coronary drug eluting stent have been filed / granted.
Question 6: How many products are marketed by companies engaged in the coronary drug eluting stent market?
Answer: Presently, more than 90 products are marketed by companies engaged in the coronary drug eluting stent market.
Question 7: Which region is the hub for companies engaged in the coronary drug eluting stent market?
Answer: Asia emerged as the hub for companies engaged in the coronary drug eluting stent market, with over 35% of the players established in the region.
